Simple.
Every day.

Boehringer Ingelheim

Lilly

TRAJENTA®

5 mg once daily

One dose, Once daily.[1]



NO DOSE REDUCTION
regardless of renal function[1]

PROVEN EFFICACY
at any stage of renal function[1,2]

Suitable for
A BROAD RANGE
of T2D patients[1]

1. TRAJENTA® Summary of Product Characteristics. June 2017. 2. McGill JB, et al. Diabetes Care. 2013;36:237-44.

Trajenta® (linagliptin) 5mg tablets

Jentadueto® (linagliptin/metformin HCl)

TRAJENTA®: The only approved* DPP4i that does not require dose reduction based on renal function[1-5]

Required DPP4i dose with declining renal function, as defined by SmPC[1-5]

Normal	Mild RI	Moderate RI	Severe RI	End-stage renal disease
5 mg OD				
100 mg OD	100 mg OD GFR ≥60 to 90 mL/min	100 mg OD GFR ≥45 to 60 mL/min	50 mg OD GFR ≥30 to 45 mL/min	25 mg OD GFR ≥15 to 30 mL/min	25 mg OD GFR <15 mL/min
5 mg OD	5 mg OD CrCl >50 to ≤80 mL/min	2.5 mg OD CrCl ≥30 to ≤50 mL/min	2.5 mg OD CrCl > 15 to <30mL/min	Not recommended CrCl < 15 mL/min
50 mg BD	50 mg BD CrCl ≥50mL/min	50 mg OD CrCl ≥30 to <50 mL/min	50 mg OD CrCl > 15 to <30 mL/min	50 mg OD ESRD on haemodialysis: use with caution
25 mg OD	25 mg OD CrCl >50 to ≤80 mL/min	12.5 mg OD CrCl ≥30 to ≤50 mL/min	6.25 mg OD CrCl > 15 to <30 mL/min	6.25 mg OD Limited experience in renal dialysis. Not studied in peritoneal dialysis

When renal function declines, no need for DPP4i dose adjustment with TRAJENTA®[1]

1. TRAJENTA® Summary of Product Characteristics. June 2017. 2. Januvia® Summary of Product Characteristics. December 2017. 3. Onglyza® Summary of Product Characteristics. August 2017. 4. Galvus® Summary of Product Characteristics. April 2017. 5. Vipidia® Summary of Product Characteristics. January 2015.
*Information is derived from the Summary of Product Characteristics (SMPC) for TRAJENTA®/JENTADUETO® in the EU. It is not country-specific and may vary from the approved label in the country where you are located. Please refer to your local Prescribing Information for full details.
BD: Bi-daily; CKD: Chronic kidney disease; CrCl: Creatinine clearance; OD: Once daily; RI: Renal impairment.

Trajenta® (linagliptin) 5mg tablets

Jentadueto® (linagliptin/metformin HCl)

TRAJENTA®: Proven efficacy with the same dose regardless of renal function[1-3]

Adjusted mean HbA_{1c} change vs placebo from baseline by degree of renal impairment (RI)*



1. Groop PH, et al. Diabetes Obes Metab. 2014;16:560-8. 2. McGill JB, et al. Diabetes Care. 2013;36:237-44. 3. TRAJENTA® Summary of Product Characteristics. June 2017.

*A small proportion of patients in these studies were receiving treatment combinations that fall outside of the licensed indications for TRAJENTA® (linagliptin).

†Prespecified subgroup analysis on pooled data from three pivotal Phase III, randomised, placebo-controlled trials: treatment in monotherapy, add-on to metformin, and add-on to metformin plus sulphonylurea. P values for between-group difference (versus placebo). Model includes continuous baseline HbA_{1c}, baseline body mass index (category), washout period, treatment, study, age group, gender, time since diagnosis of diabetes, race, renal function (MDRD), and treatment by renal function (MDRD).

‡1-year, randomised, double-blind, placebo-controlled study: treatment added to existing background therapy. Data based on analysis using LOCF (last observation carried forward).

eGFR (mL/min/1.73m2) = estimated glomerular filtration rate calculated as $175 \times (Scr)^{-1.154} \times (Age)^{-0.203} \times (0.742 \text{ if female}) \times (1.212 \text{ if Black})$; OD : Once daily; RCT: Randomised controlled trial; Scr: Serum creatinine.

Trajenta® (linagliptin) 5mg tablets

Jentadueto® (linagliptin/metformin HCl)

TRAJENTA®: One dose, once daily for your type 2 diabetes patients*[1]

Independent of:

- Renal function
- Hepatic function
- Age
- BMI
- Background T2D therapy
- Disease duration
- Ethnicity

1. TRAJENTA® Summary of Product Characteristics. June 2017.
*Indicated for use in adult patients. TRAJENTA® is contraindicated in those with hypersensitivity to any of the active substances or excipients, is not licensed for paediatric use and should not be used in pregnant women.
BMI: Body mass index.

Trajenta® (linagliptin) 5mg tablets

Jentadueto® (linagliptin/metformin HCl)